In a report released yesterday, Mark Massaro from Canaccord Genuity reiterated a Buy rating on Exact Sciences (NASDAQ: EXAS), with a price target of $62. The company’s shares closed yesterday at $51.63.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.2% and a 62.4% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Orasure Technologies, and Idexx Laboratories.
Currently, the analyst consensus on Exact Sciences is a Strong Buy with an average price target of $66.14, representing a 28.1% upside. In a report issued on July 19, Leerink Partners also maintained a Buy rating on the stock with a $76 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.60 and a one-year low of $36.10. Currently, Exact Sciences has an average volume of 2.13M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It has an intellectual property, which protects its non invasive, molecular screening technology for the detection of colorectal cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
